LADENBURG THALM/SH SH Initiates Coverage on UroGen Pharma (NASDAQ:URGN)

Investment analysts at LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma (NASDAQ:URGN) in a research report issued on Wednesday. The brokerage set a “buy” rating and a $31.00 price target on the stock. LADENBURG THALM/SH SH’s price objective indicates a potential upside of 193.56% from the stock’s current price.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $39.20.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $10.56 on Wednesday. UroGen Pharma has a 12-month low of $9.78 and a 12-month high of $20.70. The firm has a market capitalization of $247.63 million, a price-to-earnings ratio of -3.35 and a beta of 1.08. The stock’s 50 day moving average price is $10.79 and its two-hundred day moving average price is $12.26. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On UroGen Pharma

Several institutional investors have recently made changes to their positions in the stock. RTW Investments LP raised its holdings in UroGen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after acquiring an additional 47,447 shares in the last quarter. Toronto Dominion Bank acquired a new position in UroGen Pharma in the fourth quarter valued at about $18,628,000. Vestal Point Capital LP lifted its position in UroGen Pharma by 307.5% during the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after purchasing an additional 1,230,000 shares during the period. Acorn Capital Advisors LLC acquired a new stake in UroGen Pharma during the fourth quarter worth about $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in UroGen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock valued at $14,667,000 after buying an additional 36,084 shares during the period. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.